Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC6019-0001 in ATTR Cardiomyopathy
NCT05442047Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of coramitug in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Novo Nordisk. Started Aug 2022; status: completed.
02
Drugs
coramitug
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT05442047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442047.